In Silico-Driven Engineering of Halomonas elongata L-Asparaginase: Towards Enhanced Proteolytic Resistance in Lymphoblastic Leukemia
Maryam Samadaei Ghadikolaei, Sedigheh AsadiD, Vahideh Hassan‐ZadehiD
Abstract
The shortened L-asparaginases half-life in leukemia patients due to elevated serum proteases, poses a challenge. This study aimed to enhance the stability of Halomonas elongata L-asparaginase against trypsin. Employing the trRosetta server, we modeled the enzymes 3D structure with a quality score of 96.5, revealing predominant secondary structure of random coils (42%), alpha helices (33%), and extended strands (20%) organized in two domains. Molecular docking unveiled a triad alignment among residues Thr16, Ser65, and Asp97 with L-asparagine. Site selection for mutation considered secondary structure prediction, dimerization analysis, trypsin cleavage site determination and epitope mapping. A library of enzyme variants was constructed through site saturation mutagenesis which led to the identification of the Arg206 to Thr, resulting in a 1.7-fold increased enzyme-specific activity (2400 U/mg) and heightened trypsin resistance. The mutant displayed a half-life of 3.47 hin human serum, approximately 50% longer than the wild type. In silico analyses confirmed structural stability, reduced flexibility, and enhanced substrate binding, contributing to increased proteolysis resistance and enzymatic activity. The Arg206Thr mutant exhibited anti-proliferative activity (IC50 of 1.45 U/ml) on leukemia cell line K562, suggesting potential therapeutic implications.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In-silico development of a method for the selection of optimal enzymes using L-asparaginase II against Acute Lymphoblastic Leukemia as an example.
Adesh Baral, Ritesh Gorkhali, … Hitesh Kumar Bhattarai·JMIRx MedPeer-reviewed·Sep 8, 2021
- Generating an Efficient Arginase Variant for Medical and Industrial Uses: in Silico Engineering
Haitham Al‐Madhagi, Mahdi H. Alsugoor·bioRxiv·Mar 27, 2023
- Biophysical characterization of two commercially available preparations of the drug containing Escherichia coli L-Asparaginase 2
T. S. Araujo, S. M. Scapin, … L. M. T. d. R. Lima·bioRxiv·Nov 11, 2020
- Assessment of structural behaviour of new L-asparaginase and SAXS data-based evidence for catalytic activity in its monomeric form
K. N. Mihooliya, J. Nandal, … D. K. Sahoo·bioRxiv·Jan 1, 2023
- Site-specific PEGylation crosslinking of L-asparaginase subunits to improve its therapeutic efficiency
J. Ramirez-Paz, M. Saxena, … K. Griebenow·bioRxiv·May 8, 2018
- Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias
L. Hinze, M. Pfirrmann, … A. Gutierrez·bioRxiv·Sep 12, 2018